



| Substitute for form 1449A/PTO | | | | Complete if Known | | | |
|---|-----------------------|---|--------------------------------------|---|---|---|----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/697,543 | | |
| (Use several sheets if necessary) | | | | Filing Date | October 30, 2003 | | |
| | | | | First Name Inventor | Cai, et al. | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 21454 US | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initials ¹ | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited document MM-DD-YYYY | | |
| | | Number | Kind Code ² (if known) | | | | |
| JF | A1 | 4,503,049 | | Biere, et al. | 03/5/1985 | | |
| | A2 | 4,473,560 | | Biere, et al. | 09/25/1984 | | |
| | A3 | 4,784,993 | | Bosies | 11/15/1988 | | |
| | A4 | 5,866,556 | | Heikkila-Hoikka | 02/02/1999 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ³ |
| | | Office ⁴ | Number ⁴ | Kind Code ⁵ (if known) | | | |
| JF | B1 | WO | 99/61444 | | Warner Lambert Co. | 12/02/1999 | |
| | B2 | WO | 01/44258 | | Ariad Pharmaceuticals Inc. | 06/21/2001 | |
| | B3 | EP | 0 186 405 | | The Procter & Gamble Co. | 07/02/1986 | |
| | B4 | EP | 0 084 822 | | Schering Aktiengesellschaft | 08/03/1983 | |
| | B5 | EP | 0 304 962 | | The Procter & Gamble Co. | 03/01/1989 | |
| | B6 | EP | 0 085 321 | | Schering Aktiengesellschaft | 08/10/1983 | |
| | B7 | EP | 0 170 228 | | Boehringer Mannheim GmbH | 02/05/1986 | |
| | B8 | WO | 94/09017 | | The Upjohn Co. | 04/28/1994 | |
| | B9 | WO | 00/24744 | | F.Hoffmann-La Roche AG | 05/04/2000 | |
| | B10 | WO | 01/29041 | | F.Hoffmann-La Roche AG | 04/26/2001 | |
| | B11 | WO | 01/29042 | | F.Hoffmann-La Roche AG | 04/26/2001 | |
| NON PATENT LITERATURE DOCUMENTS | | | | | | | |
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | T ² | |
| JF | C1 | Kinko, K. et al., Can. J. Chem. Vol. 51 (1973) pgs. 333-337 | | | | | |
| | C2 | Merrifield, B. et al., Fed. Proc. Fed. Amer. Soc. Exp. Biol. Vol. 21 (1962) p. 412 | | | | | |
| | C3 | Okuda, T. et al., J. Org. Chem. Vol. 24 (1959) pgs. 14-16 | | | | | |
| | C4 | Ansel, H. et al., Pharm. Dosage Forms & Drug Delivery Systems (6 th Ed.), 1995 p. 196 | | | | | |
| Examiner Signature | 10/1/04 | Date Considered | | | | | |

¹EXAMINER: Initial if reference considered, whether or not cited is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form without communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

138447